{"id":"NCT01778049","sponsor":"Boehringer Ingelheim","briefTitle":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes","officialTitle":"A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2013-01-29","resultsPosted":"2016-04-04","lastUpdate":"2016-04-04"},"enrollment":708,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773 Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773 / BI 1356 Placebo","otherNames":[]}],"arms":[{"label":"Empagliflozin 10 mg dose","type":"EXPERIMENTAL"},{"label":"Placebo add on 10 mg dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin/Linagliptin 25/5 mg Dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin/Linagliptin 10/5 mg Dose.","type":"EXPERIMENTAL"},{"label":"Empagliflozin/Linagliptin 10/5 mg Dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin 25 mg dose","type":"EXPERIMENTAL"},{"label":"Empagliflozin/Linagliptin 25/5 mg Dose.","type":"EXPERIMENTAL"},{"label":"Placebo add on 25 mg dose","type":"EXPERIMENTAL"}],"summary":"The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.","primaryOutcome":{"measure":"Change From Baseline of HbA1c After 24 Weeks of Treatment.","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Lina5 (E10)","deltaMin":-0.53,"sd":0.07},{"arm":"Plc (E10)","deltaMin":-0.21,"sd":0.07},{"arm":"Lina5 (E25)","deltaMin":-0.58,"sd":0.07},{"arm":"Plc (E25)","deltaMin":-0.1,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":114,"countries":["United States","Argentina","Australia","Canada","El Salvador","Germany","Italy","Portugal","Russia","Spain","Ukraine"]},"refs":{"pmids":["27762093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":352},"commonTop":["Urinary tract infection","Lipase increased","Nasopharyngitis"]}}